^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PNK-007

i
Other names: PNK-007, PNK 007, cord blood-derived natural killer cells, PNK007, placental-derived natural killer cell therapy
Associations
Trials
Company:
BMS, Celularity
Drug class:
NK cell stimulant
Related drugs:
Associations
Trials
almost4years
[VIRTUAL] A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK‑001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592) (TCT-ASTCT-CIBMTR 2021)
In this study (NCT02781467), a single infusion of PNK-007 up to 10e6 cells/kg was administered following cyclophosphamide (Cy)-fludarabine (Flu) Lymphodepletion (LD)... To date, 1 MRD+ pt with intermediate risk AML in morphologic CR received 3 doses of CYNK-001 at 600M cell dose following induction/consolidation with venetoclax and azacitidine... CYNK-001 is a cryopreserved allogeneic, off-the-shelf NK cell investigational product derived from human placental CD34+ cells. CYNK-001 is being evaluated in patients with AML who are in CR and are MRD+. Pt enrollment under CYNK-001-AML-001 is ongoing.
Clinical • P1 data
|
CD34 (CD34 molecule)
|
Venclexta (venetoclax) • azacitidine • fludarabine IV • taniraleucel (CYNK-001) • PNK-007
almost4years
[VIRTUAL] A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK‑001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592) (TCT-ASTCT-CIBMTR 2021)
In this study (NCT02781467), a single infusion of PNK-007 up to 10e6 cells/kg was administered following cyclophosphamide (Cy)-fludarabine (Flu) Lymphodepletion (LD)... To date, 1 MRD+ pt with intermediate risk AML in morphologic CR received 3 doses of CYNK-001 at 600M cell dose following induction/consolidation with venetoclax and azacitidine... CYNK-001 is a cryopreserved allogeneic, off-the-shelf NK cell investigational product derived from human placental CD34+ cells. CYNK-001 is being evaluated in patients with AML who are in CR and are MRD+. Pt enrollment under CYNK-001-AML-001 is ongoing.
Clinical • P1 data
|
CD34 (CD34 molecule)
|
Venclexta (venetoclax) • azacitidine • fludarabine IV • taniraleucel (CYNK-001) • PNK-007
almost4years
[VIRTUAL] A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK‑001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592) (TCT-ASTCT-CIBMTR 2021)
In this study (NCT02781467), a single infusion of PNK-007 up to 10e6 cells/kg was administered following cyclophosphamide (Cy)-fludarabine (Flu) Lymphodepletion (LD)... To date, 1 MRD+ pt with intermediate risk AML in morphologic CR received 3 doses of CYNK-001 at 600M cell dose following induction/consolidation with venetoclax and azacitidine... CYNK-001 is a cryopreserved allogeneic, off-the-shelf NK cell investigational product derived from human placental CD34+ cells. CYNK-001 is being evaluated in patients with AML who are in CR and are MRD+. Pt enrollment under CYNK-001-AML-001 is ongoing.
Clinical • P1 data
|
CD34 (CD34 molecule)
|
Venclexta (venetoclax) • azacitidine • fludarabine IV • taniraleucel (CYNK-001) • PNK-007
almost4years
[VIRTUAL] A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK‑001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592) (TCT-ASTCT-CIBMTR 2021)
In this study (NCT02781467), a single infusion of PNK-007 up to 10e6 cells/kg was administered following cyclophosphamide (Cy)-fludarabine (Flu) Lymphodepletion (LD)... To date, 1 MRD+ pt with intermediate risk AML in morphologic CR received 3 doses of CYNK-001 at 600M cell dose following induction/consolidation with venetoclax and azacitidine... CYNK-001 is a cryopreserved allogeneic, off-the-shelf NK cell investigational product derived from human placental CD34+ cells. CYNK-001 is being evaluated in patients with AML who are in CR and are MRD+. Pt enrollment under CYNK-001-AML-001 is ongoing.
Clinical • P1 data
|
CD34 (CD34 molecule)
|
Venclexta (venetoclax) • azacitidine • fludarabine IV • taniraleucel (CYNK-001) • PNK-007
almost4years
[VIRTUAL] A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK‑001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592) (TCT-ASTCT-CIBMTR 2021)
In this study (NCT02781467), a single infusion of PNK-007 up to 10e6 cells/kg was administered following cyclophosphamide (Cy)-fludarabine (Flu) Lymphodepletion (LD)... To date, 1 MRD+ pt with intermediate risk AML in morphologic CR received 3 doses of CYNK-001 at 600M cell dose following induction/consolidation with venetoclax and azacitidine... CYNK-001 is a cryopreserved allogeneic, off-the-shelf NK cell investigational product derived from human placental CD34+ cells. CYNK-001 is being evaluated in patients with AML who are in CR and are MRD+. Pt enrollment under CYNK-001-AML-001 is ongoing.
Clinical • P1 data
|
CD34 (CD34 molecule)
|
Venclexta (venetoclax) • azacitidine • fludarabine IV • taniraleucel (CYNK-001) • PNK-007
5years
Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma (ASH 2019)
Translational data from a Phase I study of PNK-007 in post-ASCT MM established that dosing up to 3x107 cells/kg at 14 or 7 days post-transplant did not impair engraftment or immune reconstitution. EuroFlow MRD assessment of the bone marrow showed conversion of 6/11 patients from MRD(+) to MRD(-) by day 90 post transplant. The administration of IL-2 in this clinical study did not appear to benefit NK cell reconstitution but instead favored soluble IL2RA antagonism and increased systemic levels of Treg.
P1 data
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule)
|
PNK-007
5years
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550) (ASH 2019)
PNK-007 is the first fully allogeneic, off the shelf CD34+ derived NK cell product in MM clinical trials. A single infusion of PNK-007 up to 30M cells/kg with and without rhIL-2 was well tolerated in the post-ASCT setting. We established the feasibility of infusing PNK-007 as early as 7 days post-ASCT without negative impact on blood count recovery or successful engraftment.
P1 data
|
CD34 (CD34 molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1)
|
PNK-007
5years
Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy (ASH 2019)
Celularity has developed a GMP process for generating off-the-shelf and allogeneic human Placental Hematopoietic Stem Cell derived Natural Killer (PNK-007) cells... The novel PNK-CAR38 demonstrated enhanced in vitro cytotoxic potential against lymphoma and MM lines and showed no on-target off-tumor cytotoxicity against healthy donor-derived cells in vitro. In vivo anti-tumor activity of PNK-CAR38 was shown in a lymphoma disseminated NSG model. Further development of PNK-CAR38 for hematological malignancies is warranted.
IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1)
|
PNK-007 • ROR1.TNK